Treatment of pulmonary and retroperitoneal lymphangioleiomyomatosis with rapamycin: a case presentation and literature review.
- Author:
Dandan ZONG
1
;
Ruoyun OUYANG
Author Information
1. Department of Respiratory Medicine, Central South University, Changsha, China.
- Publication Type:Case Reports
- MeSH:
Female;
Humans;
Lung Neoplasms;
complications;
drug therapy;
Lymphangioleiomyomatosis;
drug therapy;
Middle Aged;
Retroperitoneal Neoplasms;
complications;
drug therapy;
Sirolimus;
therapeutic use
- From:
Journal of Central South University(Medical Sciences)
2012;37(9):963-967
- CountryChina
- Language:Chinese
-
Abstract:
To improve the diagnosis and treatment of pulmonary lymphangiomyomatosis, clinical data for the first successfully treated case of pulmonary and retroperitoneal lymphangiomyomatosis in our hospital has been comprehensively analyzed, and the relevant literature has been reviewed. A 45-year-old Han Chinese woman initially presented six months ago with increasing shortness of breath on exertion and was admitted to our hospital after four days of chest pain. Admission examination revealed chylothorax, interstitial lung disease, and enlarged retroperitoneal lymph nodes. The patient was finally diagnosed with pulmonary and retroperitoneal lymphangiomyomatosis based on laparotomy examination and biopsy of the retroperitoneal lymph nodes. After six months of rapamycin treatment, the symptoms - lung function, arterial blood gas, and imaging of the patient- were improved significantly. Pulmonary lymphangiomyomatosis clinically manifests as progressive dyspnea, recurrent pneumothorax, and chylothorax, and can be diagnosed by its characteristic features in high-resolution computed tomographic images or pathological examination. The successful treatment of pulmonary lymphangiomyomatosis with rapamycin brings new hope to those afflicted with this disease.
